Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.60 |
| ▸ | GSK3B | P49841 | 8/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286713 | 1.00 | CDK2 (0.60) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22286675 | 0.87 | CCNE1 (0.69) | CDK2CCNE1GSK3B | |
| SCHEMBL22286726 | 0.87 | CCNE1 (0.69) | CDK2CCNE1GSK3B | |
| SCHEMBL22286790 | 0.86 | CDK2 (0.64) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22286851 | 0.86 | CDK2 (0.64) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22286808 | 0.84 | CDK2 (0.61) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL25334996 | 0.83 | CDK2 (0.80) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22286760 | 0.81 | CDK2 (0.61) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22287144 | 0.81 | CDK2 (0.61) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL22287151 | 0.80 | CDK2 (0.79) | CDK2CCNE1GSK3BCCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014911-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200247784-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247784-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | CDK2 1/4885CCNE1 8/4885GSK3B 114/4885 |
| US-11014911-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CDK2 1/4885CCNE1 8/4885GSK3B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.